Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Completed

• Conditions: Wet AMD
• Interventions: Drug: Lucentis

• Registration Number: NCT00804934
• Lead Sponsor: Retina Institute of Hawaii

Brief Summary

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Detailed Description

To determine mean change in visual acuity at 6 and 12 months

Study Timeline

• Study Start: 2008-02
• Primary Completion: 2008-02
• Study First Submitted: 2008-12-05
• Study First Submitted QC: 2008-12-08
• Study First Posted: 2008-12-09
• Study Completion: 2009-01
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-24
• Last Update Posted: 2012-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age greater then and equal 50 years
• Patients with active neovascular AMD
• Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
• If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion Criteria

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy or lactation
• Premenopausal women not using adequate contraception.
• Participation in another simultaneous medical investigation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
0	Lucentis	-

Primary Outcome Measures

Name	Time	Method
Mean change in visual acuity at 6 and 12 months	one year

Trial Locations

Locations (1)

Retina Institute of Hawaii; 🇺🇸 Honolulu, Hawaii, United States